ezrin在乳腺癌中的表达及其临床意义

Expression and clinical significance of ezrin in breast carcinomas.

目的探讨乳腺癌组织中ezrin蛋白的表达及其临床意义。方法应用免疫组化S-P方法，检测63例乳腺癌组织中ezrin的表达情况。结果ezrin总的表达率为55．56％（35／63），ezrin表达率随着淋巴结转移增多和临床分期的增高而升高（χ^2分别为7．718、6．760，P分别为0．005、0．009）。无病生存时间在5年以上患者的ezrin表达率[33．33％（10／30）]显著低于无病生存时间不足5年（远处转移）或5年内死亡的患者（75．76％，25／33，χ^2=11．455，P=0．001），但是ezrin的表达和肿瘤大小、月经及年龄无相关性（χ^2分别为0．060、0．423、0．319，P均〉0．05）。结论检测ezrin在乳腺癌中的表达可能有助于对其预后的判断。

Objective To study the expression and clinical significance of ezrin in breast carcinoma. Methods Immunohistochemical staining（S-P） was used to detect the expression of ezrin in 63 cases of breast carcinoma samples. Results Among these 63 samples, the total expression rates of ezrin were 55.56% （35/63）. With the increasing of axillary lymph nodes metastasis and clinical staging, the rates of expressing of ezrin elevated （P 〈0.05 ）, which was remarkably lower in patients whose disease-free survival （DFS） was 〉 5 years, or those whose DFS≤5 years or died within five years（P 〈0.05） ,but the expression of ezrin was not correlated with tumor size, age and menopausal status （ P 〉 0.05 ）. Conclusion The expression of ezrin may contribute to prognostic evaluation for breast carcinoma.